Journal Finder

Current Computer-Aided Drug Design aims to publish all the latest developments in drug design based on computational techniques. The field of computer-aided drug design has had extensive impact in the area of drug design.

Current Drug Targets aims to cover the latest and most outstanding developments on the medicinal chemistry and pharmacology of molecular drug targets e.g. disease specific proteins, receptors, enzymes, genes.

Current Enzyme Inhibition aims to publish original research, review and letter articles in all the latest and outstanding developments on enzyme inhibition studies. The coverage includes the mechanisms of inhibitory processes of enzymes, recognition of active sites, and the discovery of agonists and antagonists, leading to the design and development of new drugs of significant therapeutic value. Current Enzyme Inhibition is an essential journal for every pharmaceutical researcher and medicinal chemist who wishes to have up-to-date knowledge about each and every development in the study of enzyme inhibition.

Current Gene Therapy is a bi-monthly peer-reviewed journal aimed at academic and industrial scientists with an interest in major topics concerning basic research and clinical applications of gene and cell therapy of genetic diseases. Cell therapy manuscripts can also include application in non-genetic diseases when cells have been genetically modified. Current Gene Therapy publishes reviews and original research on the latest developments in gene transfer and gene expression analysis, vector development, cellular genetic engineering, animal models and human clinical applications of gene and cell therapy for the treatment of genetic diseases.

Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews and guest edited thematic issues written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.

Current Molecular Medicine is an interdisciplinary journal focused on providing the readership with current and comprehensive reviews, original research articles, short communications/letters and drug clinical trial studies on fundamental molecular mechanisms of disease pathogenesis, the development of molecular-diagnosis and/or novel approaches to rational treatment. The reviews should be of significant interest to basic researchers and clinical investigators in molecular medicine. Periodically the journal invites guest editors to devote an issue on a basic research area that shows promise to advance our understanding of the molecular mechanism(s) of a disease or has potential for clinical applications.

Current Pharmaceutical Analysis publishes expert reviews and original research articles on all the most recent advances in pharmaceutical and biomedical analysis. All aspects of the field are represented including drug analysis, analytical methodology and instrumentation. The journal is essential to all involved in pharmaceutical, biochemical and clinical analysis.

Current Pharmacogenomics and Personalized Medicine (CPPM) is a transdisciplinary peer-reviewed biomedical journal that reports new findings and cutting-edge concepts in both pharmacogenomics and personalized medicine under a single cover. CPPM is an accelerator for global personalized medicine and pharmacogenomics. Importantly, the journal provides a multi-disciplinary integrated platform from cell to society to address diagnostics and responsible pharmacogenomics applications in developing countries.

Cytotherapy is the Official Journal of the International Society for Cellular Therapy (ISCT).Cytotherapy publishes cutting edge findings, clinical trials of cell-based therapies, and news and opinion on all aspects of the rapidly expanding field of cell-based treatments for cancer, degenerative disorders, immunotherapy and stem cell transplantation. The journal focuses especially on the practical translation of scientific developments in the laboratory into clinical practice. Cytotherapy is an essential global resource for clinical researchers, oncologists, hematologists, physicians, and regulatory experts involved in cell processing and therapy.The journal's scope includes research in:Stem cell processing and transplantationCell-based therapies of malignant and non-malignant blood diseasesCancerStem cell plasticityAutoimmune diseasesImmunotherapyCongenital disordersNovel molecular therapiesGene therapyMicrovesicle biology and therapeutic application

Dalton Transactions publishes high-quality original research, theoretical and computational studies that significantly advance the field of inorganic chemistry. Its scope includes organometallic, bioinorganic, medicinal inorganic, materials and nanomaterials, with applications including synthesis, catalysis, energy conversion/storage, electrical devices and medicine and sensors.

The Drug Discovery Today reviews collection provides a resource of review content aligning the key output of human molecular medicine with the specific requirements of the drug discovery process. It is designed to systematically cover the essential elements of molecular medicine and drug discovery, in a manner that has relevance to those actually working on the discovery and development of new drugs. This collection will evolve to create a highly structured database and will act as a one-stop-shop for high quality content.Other titles in this series include:Drug Discovery Today: Disease ModelsDrug Discovery Today: Therapeutic StrategiesDrug Discovery Today: TechnologiesDrug Discovery Today: Disease Mechanisms covers the analysis of the molecules and pathways that fail or are subverted during the aetiology and pathogenesis of human disease. It focuses on what is actually known or strongly predicted about the human disease process.There will be 4 issues each year. The Drug Discovery Today reviews collection is only available online.Ethics in Publishing: General StatementThe Editor(s) and Publisher of this Journal believe that there are fundamental principles underlying scholarly or professional publishing. While this may not amount to a formal 'code of conduct', these fundamental principles with respect to the authors' paper are that the paper should: i) be the authors' own original work, which has not been previously published elsewhere, ii) reflect the authors' own research and analysis and do so in a truthful and complete manner, iii) properly credit the meaningful contributions of co-authors and co-researchers, iv) not be submitted to more than one journal for consideration, and v) be appropriately placed in the context of prior and existing research. Of equal importance are ethical guidelines dealing with research methods and research funding, including issues dealing with informed consent, research subject privacy rights, conflicts of interest, and sources of funding. While it may not be possible to draft a 'code' that applies adequately to all instances and circumstances, we believe it useful to outline our expectations of authors and procedures that the Journal will employ in the event of questions concerning author conduct. With respect to conflicts of interest, the Publisher now requires authors to declare any conflicts of interest that relate to papers accepted for publication in this Journal. A conflict of interest may exist when an author or the author's institution has a financial or other relationship with other people or organizations that may inappropriately influence the author's work. A conflict can be actual or potential and full disclosure to the Journal is the safest course. All submissions to the Journal must include disclosure of all relationships that could be viewed as presenting a potential conflict of interest. The Journal may use such information as a basis for editorial decisions and may publish such disclosures if they are believed to be important to readers in judging the manuscript. A decision may be made by the Journal not to publish on the basis of the declared conflict. For more information, please refer to: http://www.elsevier.com/wps/find/authorshome.authors/conflictsofinterest.

The Drug Discovery Today reviews collection provides a resource of review content aligning the key output of human molecular medicine with the specific requirements of the drug discovery process. It is designed to systematically cover the essential elements of molecular medicine and drug discovery, in a manner that has relevance to those actually working on the discovery and development of new drugs. This collection will evolve to create a highly structured database and will act as a one-stop-shop for high quality content.Drug Discovery Today: Disease Models discusses the non-human experimental models through which inference is drawn regarding the molecular aetiology and pathogenesis of human disease. It provides critical analysis and evaluation of which models can genuinely inform the research community about the direct process of human disease, those which may have value in basic toxicology, and those which are simply designed for effective expression and raw characterisation.Other titles in this series include:Drug Discovery Today: Disease MechanismsDrug Discovery Today: Therapeutic StrategiesDrug Discovery Today: TechnologiesThere will be four issues each year.The Drug Discovery Today reviews collection is only available online.Ethics in Publishing: General StatementThe Editor(s) and Publisher of this Journal believe that there are fundamental principles underlying scholarly or professional publishing. While this may not amount to a formal 'code of conduct', these fundamental principles with respect to the authors' paper are that the paper should: i) be the authors' own original work, which has not been previously published elsewhere, ii) reflect the authors' own research and analysis and do so in a truthful and complete manner, iii) properly credit the meaningful contributions of co-authors and co-researchers, iv) not be submitted to more than one journal for consideration, and v) be appropriately placed in the context of prior and existing research. Of equal importance are ethical guidelines dealing with research methods and research funding, including issues dealing with informed consent, research subject privacy rights, conflicts of interest, and sources of funding. While it may not be possible to draft a 'code' that applies adequately to all instances and circumstances, we believe it useful to outline our expectations of authors and procedures that the Journal will employ in the event of questions concerning author conduct. With respect to conflicts of interest, the Publisher now requires authors to declare any conflicts of interest that relate to papers accepted for publication in this Journal. A conflict of interest may exist when an author or the author's institution has a financial or other relationship with other people or organizations that may inappropriately influence the author's work. A conflict can be actual or potential and full disclosure to the Journal is the safest course. All submissions to the Journal must include disclosure of all relationships that could be viewed as presenting a potential conflict of interest. The Journal may use such information as a basis for editorial decisions and may publish such disclosures if they are believed to be important to readers in judging the manuscript. A decision may be made by the Journal not to publish on the basis of the declared conflict.For more information, please refer to: http://www.elsevier.com/wps/find/authorshome.authors/conflictsofinterest

The Drug Discovery Today reviews collection provides a resource of review content aligning the key output of human molecular medicine with the specific requirements of the drug discovery process. It is designed to systematically cover the essential elements of molecular medicine and drug discovery, in a manner that has relevance to those actually working on the discovery and development of new drugs. This collection will evolve to create a highly structured database and will act as a one-stop-shop for high quality content.

The Drug Discovery Today reviews collection provides a resource of review content aligning the key output of human molecular medicine with the specific requirements of the drug discovery process. It is designed to systematically cover the essential elements of molecular medicine and drug discovery, in a manner that has relevance to those actually working on the discovery and development of new drugs.This collection will evolve to create a highly structured database and will act as a one-stop-shop for high quality content.What are the biotechnical challenges in ensuring drug action, especially with regard to biopharmaceuticals? Drug Discovery Today: Therapeutic Strategies discusses the varied strategies used, including stem-cell therapy, vaccination, gene therapy, tissue modelling, tissue and non-tissue implants and many others.Other titles in this series include:Drug Discovery Today: Disease MechanismsDrug Discovery Today: Disease ModelsDrug Discovery Today: TechnologiesThere will be four issues each year. The Drug Discovery Today reviews collection is only available online.Ethics in Publishing: General StatementThe Editor(s) and Publisher of this Journal believe that there are fundamental principles underlying scholarly or professional publishing. While this may not amount to a formal 'code of conduct', these fundamental principles with respect to the authors' paper are that the paper should: i) be the authors' own original work, which has not been previously published elsewhere, ii) reflect the authors' own research and analysis and do so in a truthful and complete manner, iii) properly credit the meaningful contributions of co-authors and co-researchers, iv) not be submitted to more than one journal for consideration, and v) be appropriately placed in the context of prior and existing research. Of equal importance are ethical guidelines dealing with research methods and research funding, including issues dealing with informed consent, research subject privacy rights, conflicts of interest, and sources of funding. While it may not be possible to draft a 'code' that applies adequately to all instances and circumstances, we believe it useful to outline our expectations of authors and procedures that the Journal will employ in the event of questions concerning author conduct. With respect to conflicts of interest, the Publisher now requires authors to declare any conflicts of interest that relate to papers accepted for publication in this Journal. A conflict of interest may exist when an author or the author's institution has a financial or other relationship with other people or organizations that may inappropriately influence the author's work. A conflict can be actual or potential and full disclosure to the Journal is the safest course. All submissions to the Journal must include disclosure of all relationships that could be viewed as presenting a potential conflict of interest. The Journal may use such information as a basis for editorial decisions and may publish such disclosures if they are believed to be important to readers in judging the manuscript. A decision may be made by the Journal not to publish on the basis of the declared conflict. For more information, please refer to: http://www.elsevier.com/wps/find/authorshome.authors/conflictsofinterest.

The journal publishes original research reports, authoritative reviews and case reports of experimental and clinical sciences.

Journal of clinical and molecular medicine is a quarterly, peer-reviewed journal providing a platform for advances in health care/clinical practices in combination with basic findings in mechanisms of disease pathogenesis to therapy.

Cumulative of clinical practices with an insight for researchers within the community in regard to developing molecular tools and identifying molecular targets for the diagnosis and treatment of a diverse number of human diseases is the primary goal of Journal.

Journal will feature research, review papers, reports, editorials, expert opinion and perspective papers, commentaries, and book reviews.

Journal of clinical and molecular medicine accepts direct submissions from authors: Attach your word file with e-mail and send it to: submissions@oatext.com  alternatively to editor.jcmm@oatext.com

Please, follow the Instructions for Authors. In the cover letter add the name and e-mail address of 5 proposed reviewers (we can choose them or not).

Copyright is retained by the authors and articles can be freely used and distributed by others. Articles are distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published by Journal of clinical and molecular medicine, is properly cited.

EXPERIMENTAL and MOLECULAR MEDICINE, EMM, publishes research papers and a limited number of reviews in the fields of basic and applied molecular biology, and experimental biochemistry in medicine. Research areas include analysis of gene structure, function and regulation; molecular mechanisms of genetic recombination; recombinant nucleic acid technology and gene therapy. EMM is also dedicated to the experimental biochemistry in medicine, including the regulatory mechanisms of body functions; structural biology and interaction between proteins and/or nucleic acids. Although special research areas are emphasized for publication, articles dealing with molecular biology and experimental biochemistry in other areas will also be welcomed.